Nektar Therapeutics (NKTR)

Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus

Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript

Nektar Therapeutics Q2 Earnings Call Highlights

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm

Nektar Therapeutics (NKTR) to Release Quarterly Earnings on Thursday

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?

Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Up – What’s Next?

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitis

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year

3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York